Myeloproliferace
- MUDr. Jiří Schwarz, CSc., Ústav hematologie a krevní transfuze, Praha
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Otevřít | 2014 | MUDr. Petra Čičátková
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Otevřít | 2014 | MUDr. Petra Čičátková
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Otevřít | 2013 | MUDr. Petra Čičátková
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplazma Research and Treatment (IWG-MRT) and European LeukemiaNer (ALN) consensus report
Otevřít | 2013 | MUDr. Petra Čičátková
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Otevřít | 2013 | MUDr. Petra Čičátková
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
Otevřít | 2013 | prof. MUDr. Michael Doubek, Ph.D.
JAK Inhibitor with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Otevřít | 2012 | MUDr. Petra Čičátková
Assessment an prognostic value of the European LeukemiaNet criteria for clinicohematological response, resistence, and intolerance to hydroxyurea in polycytemia vera
Otevřít | 2012 | MUDr. Petra Čičátková
A prognostic model to predict survival in 867 World Health Organization – defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
Otevřít | 2012 | MUDr. Petra Čičátková
A Double-blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Otevřít | 2012 | MUDr. Petra Čičátková
Guideline for investigation and management of adults and children presenting with a thrombocytosis
Otevřít | 2010 | MUDr. Štěpán Hrabovský
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working party of the European Group for Blood and marrow Transplantation
Otevřít | 2009 | doc. MUDr. Michael Doubek, Ph.D.
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
Otevřít | 2009 | MUDr. František Folber
New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment
Otevřít | 2009 | MUDr. František Folber
JAK2V617F mutation for the early diagnosis of Ph– myeloproliferative neoplasms in patient with venous trombosis: a meta-analysis
Otevřít | 2009 | MUDr. Petra Čičátková
A gain-of-function mutation of JAK2 in myeloproliferative disorders
Otevřít | 2005 | MUDr. Jitka Kujíčková